Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash


Gen-Probe (Nasdaq: GPRO), a maker of disease diagnosis products based in San Diego, announced today that it has acquired privately-held GTI Diagnostics for $53 million in cash.

GTI produces a number of immune system-related testing products, including ones that measure a patient's immune response to therapies for bleeding disorders.  Wisconsin-based GTI also produces the white blood cell detection products sold by Gen-Probe under the Lifecodes brand. 

"Acquiring GTI enables us to broaden and strengthen our transplant diagnostics business," said Carl Hull, Gen-Probe's CEO.

"In addition, the acquisition gives us access to growing coagulation and transfusion-related blood bank products that we can sell to our current customer base."

Excluding acquisition charges, which have not yet been estimated, Gen-Probe said it expects the deal to be slightly accretive to its 2011 earnings per share. 

The deal was financed by the cash Gen-Probe had on hand. As of September 30, the company had about $149 million of cash. 

Gen-Probe’s shares have edged up by 0.5% to trade at $57.86 as of 11:33 am EST.

Quick facts: Gen-Probe

Price: 6.49 USD

Market: NASDAQ
Market Cap: $1.02 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Lotus Resources reveals highlights on scoping study at its Kayelekera...

Lotus Resources Ltd (ASX:LOT) Managing Director Eduard Smirnov tells Proactive the group's Kayelekera Uranium Project can be among first uranium projects to begin production to meet the impending uranium supply shortfall. Smirnov says according to the study, the project will have a long mine...

18 hours, 29 minutes ago

2 min read